Earlier studies reported the therapeutic effect of Gal-3 inhibition in chronic inflammatory disorders with targeted delivery likelihood which underlines the possibility of Gal-3 being a potential therapeutic target in periodontal disease [47]. Here, LGALS3 is linked to periodontal disorder.